Premier Perspectives The blog for insider insights in clinical development Recent Posts By expertise area All expertise areas Medical DeviceRare DiseaseOncology & HematologyDiagnosticsDigital TherapeuticsMedTechPediatricsNeuroscienceAnalgesiaDermatologyOtherCOVID-19Cell & Gene TherapyWomen's HealthReal-World & Late PhaseLife at Premier By functional area All functional areas Development StrategyClinical Research: Phase 1 - Phase 4ConsultingData Management & BiostatisticsFunctional Service Provider (FSP)Global ComplianceMedical and Regulatory AffairsPatient and Stakeholder EngagementProject ManagementQualityReal-World Science and Late PhaseSafety/PharmacovigilanceStudy DesignStudy Start-UpOtherCOVID-19Product Development Consulting How to Position Your Program to Investors: Leveraging FDA Feedback to Communicate Risk and Boost Confidence By Premier Consulting May 7, 2024 Consulting Three Keys to Preparing Effective Pre-IND Meeting Questions By Premier Consulting May 2, 2024 Medical and Regulatory Affairs FDA’s Final Rule on LDTs and Its Impact on Clinical and Regulatory Professionals By Charles Chrisawn April 30, 2024 Consulting 3 Characteristics of a Successful Cell and Gene Therapy Nonclinical Program By Madelyn Huang April 24, 2024 Consulting Design Considerations in Nonclinical Development of Cell and Gene Therapies By Premier Research April 23, 2024 Medical and Regulatory Affairs 4 Scenarios When High Risk Devices May Be Exempt from Mandatory Clinical Investigations Under EU MDR By Premier Research April 17, 2024 Previous 1 2 3 4 5 … 59 Next × ALSO OF INTERESTKey Considerations When Designing a Phase 1...Nostalgia or Shell Shock? Assessing PTSD Is a...Gene Therapy 101: From the 1960s to Today